DK2475645T3 - 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler - Google Patents

5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler

Info

Publication number
DK2475645T3
DK2475645T3 DK10749873.5T DK10749873T DK2475645T3 DK 2475645 T3 DK2475645 T3 DK 2475645T3 DK 10749873 T DK10749873 T DK 10749873T DK 2475645 T3 DK2475645 T3 DK 2475645T3
Authority
DK
Denmark
Prior art keywords
trifluor
dichlor
nicotinamide
ethoxy
cyclohexyl
Prior art date
Application number
DK10749873.5T
Other languages
Danish (da)
English (en)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2475645T3 publication Critical patent/DK2475645T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK10749873.5T 2009-09-11 2010-09-08 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler DK2475645T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (1)

Publication Number Publication Date
DK2475645T3 true DK2475645T3 (da) 2013-07-22

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10749873.5T DK2475645T3 (da) 2009-09-11 2010-09-08 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler

Country Status (34)

Country Link
US (1) US8227491B2 (enExample)
EP (1) EP2475645B1 (enExample)
JP (1) JP5604520B2 (enExample)
KR (1) KR101382871B1 (enExample)
CN (1) CN102639506B (enExample)
AR (2) AR078352A1 (enExample)
AU (1) AU2010294277B2 (enExample)
BR (1) BR112012005511B8 (enExample)
CA (1) CA2771493C (enExample)
CL (1) CL2012000611A1 (enExample)
CO (1) CO6491033A2 (enExample)
CR (1) CR20120089A (enExample)
CY (1) CY1114377T1 (enExample)
DK (1) DK2475645T3 (enExample)
EC (1) ECSP12011723A (enExample)
ES (1) ES2423821T3 (enExample)
HR (1) HRP20130869T1 (enExample)
IL (1) IL217920A (enExample)
IN (1) IN2012DN00763A (enExample)
MA (1) MA33563B1 (enExample)
MX (1) MX2012002254A (enExample)
MY (1) MY161103A (enExample)
NZ (1) NZ597514A (enExample)
PE (1) PE20120863A1 (enExample)
PL (1) PL2475645T3 (enExample)
PT (1) PT2475645E (enExample)
RS (1) RS52987B (enExample)
RU (1) RU2541475C2 (enExample)
SG (1) SG179035A1 (enExample)
SI (1) SI2475645T1 (enExample)
TW (1) TWI412363B (enExample)
UA (1) UA107088C2 (enExample)
WO (1) WO2011029827A1 (enExample)
ZA (1) ZA201201599B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
CN101155781B (zh) * 2005-04-06 2012-11-07 霍夫曼-拉罗奇有限公司 作为cb1逆激动剂的吡啶-3-甲酰胺衍生物
CA2664119A1 (en) * 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Also Published As

Publication number Publication date
BR112012005511A2 (pt) 2016-04-19
PL2475645T3 (pl) 2013-12-31
CN102639506B (zh) 2014-09-03
JP5604520B2 (ja) 2014-10-08
WO2011029827A1 (en) 2011-03-17
AR114032A2 (es) 2020-07-15
PT2475645E (pt) 2013-08-05
CO6491033A2 (es) 2012-07-31
JP2013504534A (ja) 2013-02-07
HRP20130869T1 (hr) 2013-10-25
KR20120048040A (ko) 2012-05-14
ECSP12011723A (es) 2012-04-30
EP2475645A1 (en) 2012-07-18
CA2771493A1 (en) 2011-03-17
US8227491B2 (en) 2012-07-24
SI2475645T1 (sl) 2013-10-30
MY161103A (en) 2017-04-14
RU2541475C2 (ru) 2015-02-20
CR20120089A (es) 2012-03-22
RU2012113924A (ru) 2013-10-20
ES2423821T3 (es) 2013-09-24
RS52987B (sr) 2014-02-28
BR112012005511B1 (pt) 2021-03-02
EP2475645B1 (en) 2013-07-03
IL217920A0 (en) 2012-03-29
AU2010294277B2 (en) 2015-07-09
MA33563B1 (fr) 2012-09-01
AU2010294277A1 (en) 2012-02-09
PE20120863A1 (es) 2012-07-23
CN102639506A (zh) 2012-08-15
CY1114377T1 (el) 2016-08-31
KR101382871B1 (ko) 2014-04-08
IN2012DN00763A (enExample) 2015-06-26
IL217920A (en) 2015-11-30
ZA201201599B (en) 2012-11-28
CA2771493C (en) 2017-08-29
BR112012005511B8 (pt) 2021-05-25
US20110065759A1 (en) 2011-03-17
UA107088C2 (xx) 2014-11-25
MX2012002254A (es) 2012-03-16
NZ597514A (en) 2013-10-25
AR078352A1 (es) 2011-11-02
TW201114427A (en) 2011-05-01
TWI412363B (zh) 2013-10-21
CL2012000611A1 (es) 2012-09-07
SG179035A1 (en) 2012-04-27
HK1172021A1 (en) 2013-04-12

Similar Documents

Publication Publication Date Title
NO2022018I1 (no) Avacopan samt farmaceutisk acceptable salte deraf
DK2475645T3 (da) 5-(3,4-dichlor-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluor-ethoxy)-nicotinamid og salte deraf som hdl cholesterol-løftende midler
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
BRPI1005995A2 (pt) implemento médico para manipular suturas, particularmente útil em cirurgia artroscópia
EP2152184A4 (en) SURGICAL MANIPULATOR
EP1962961A4 (en) HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
BRPI0818311A2 (pt) manipulador médico
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
ATE509020T1 (de) 3-cyano-4-(4-tetrahydropyranphenyl)pyridin-2- onderivate
EP1901635A4 (en) SUPPORT FOR PATIENT
EP2432776A4 (en) METHYLSULFANYLPYRIMIDINES USEFUL AS ANTI-INFLAMMATORY, ANALGESIC AND ANTI-EPILEPTIC AGENTS
ATE541850T1 (de) Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
EP2170232A4 (en) LASER FOR REJUVENATING THE NETWORK SKIN
EP1908389A4 (en) MEDICAL CONTROLLER
BRPI0815440A2 (pt) 5-substituidos 2- (alcoximetil) furanos
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
DK2445883T3 (da) Heterocykliske sulfonamider, anvendelser og farmaceutiske sammensætniger deraf
BRPI0813384A2 (pt) Suspensões de ingrediente ativo em glicerina
PT2306948T (pt) Dispositivo para a cirurgia a laser oftalmológica, particularmente refrativa
BRPI1015416A2 (pt) "método para operar alto-forno"
BRPI0924140A2 (pt) pinça de microcirurgia, em particular pinça de capsulorrexe por microincisão
EP2040541A4 (en) ADJUVANTS AND METHODS OF USE
DK2122101T3 (da) Indretning med forhæng, som kan rulles op
DK2155717T3 (da) 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl-pyraziner og -pyridiner og 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl-pyridiner som 5-ht7-receptorantagonister
EP2074770A4 (en) LINK AGGREGATION